文献速递妇科

前哨淋巴结定位在子宫内膜不典型增生管理中的效用

The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
PubMed 文献 · Gynecol Oncol · 2017-12-28

回顾性分析120例术前诊断为不典型增生并接受前哨淋巴结定位及盆腔淋巴结清扫的患者,术后病理证实子宫内膜癌53.3%(64/120),淋巴结受累3.3%(4/120)。术前诊断「仅不典型增生」者无淋巴结转移(0/31),「不典型增生-不能排除癌」者淋巴结转移率12.1%(4/33)。作者认为前者可省略淋巴结评估,后者前哨淋巴结定位是有价值的分别程序。

要点

  • 术前诊断仅不典型增生者术后无淋巴结转移(0/31),作者认为可省略淋巴结评估。
  • 术前诊断不典型增生-不能排除癌者淋巴结转移率12.1%(4/33)。
  • 双侧前哨淋巴结定位的子宫内膜癌患者敏感度66.6%、阴性预测值97.9%。

核心结论

  • 术前诊断仅不典型增生者淋巴结受累风险为零,可省略淋巴结评估;而不典型增生-不能排除癌者风险显著,前哨淋巴结定位可能是有价值的分别程序。

研究设计与样本

  • 回顾性分析120例术前诊断为不典型增生、接受初次手术并前哨淋巴结定位后行盆腔淋巴结清扫的患者。

主要发现

  • 术后病理证实子宫内膜癌53.3%(64/120):IA期58例、IB期3例、IIIC1期3例。
  • 术前诊断仅不典型增生者术后子宫内膜癌发生率44.3%(31/70),低于不典型增生-不能排除癌者的66%(33/50),P=0.02。
  • 总体淋巴结受累率3.3%(4/120);仅不典型增生组淋巴结转移0/31,不典型增生-不能排除癌组12.1%(4/33),P=0.06。
  • 术前CA125升高(>25U/mL)与最终病理淋巴结转移风险有统计学关联,P=0.024。
  • 单侧和双侧前哨淋巴结检出率分别为93.7%和78.1%;双侧定位的子宫内膜癌患者敏感度66.6%、阴性预测值97.9%,有1例假阴性(非前哨淋巴结中见孤立肿瘤细胞)。

临床怎么用

  • 作者认为术前诊断仅不典型增生者可省略淋巴结评估,而不典型增生-不能排除癌者前哨淋巴结定位可能是有价值的分别程序。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the risk of endometrial cancer (EC) and lymph node involvement in patients with a preoperative diagnosis of "AH-only" versus "AH - cannot rule out carcinoma" and to study the value of SLN mapping. METHODS: We reviewed all patients with a preoperative diagnosis of atypical hyperplasia, who underwent primary surgery with SLN mapping followed by pelvic lymphadenectomy. Sensitivity and negative predictive value (NPV) of SLN and rates of endometrial cancer were calculated. RESULTS: Overall, 64/120 (53.3%) patients were found to have EC on final pathology: 58 stage IA, 3 IB, and 3 IIIC1. In patients with preoperative diagnosis of "AH", 44.3% (31/70) had EC on final pathology compared to 66% (33/50) in patients with "AH - cannot rule out cancer" (p=0.02). Overall, 3.3% of the patients (4/120) had lymph node involvement. In patients with EC with a pre-operative diagnosis of "AH", none had lymph node metastasis (0/31), compared to 12.1% (4/33) in patients with "AH - cannot rule out cancer" (p=0.06). Elevated preoperative CA125 levels (>25U/mL) were statistically associated with the risk of lymph node metastasis on final pathology (p=0.024). Unilateral and bilateral SLN detection occurred in 93.7% and 78.1% respectively. In patients with EC and bilateral SLN mapping, sensitivity and NPV were respectively 66.6% and 97.9%. There was one false negative (ITCs in non-SLN). CONCLUSION: Our data indicate that the risk of lymph node involvement in patients with a preoperative diagnosis of "AH-only" is null. Lymph node assessment could be omitted in those patients. Conversely this risk is significant in patients with "AH - cannot rule out cancer". SLN mapping could be a valuable staging procedure in these patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Touhami O, Grégoire J, Renaud MC, et al. The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia. Gynecol Oncol. 2017. PMID: 29290489. doi:10.1016/j.ygyno.2017.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。